Geode Capital Management LLC Increases Holdings in argenx SE (NASDAQ:ARGX)

Geode Capital Management LLC boosted its position in argenx SE (NASDAQ:ARGX) by 1.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,207 shares of the company’s stock after buying an additional 458 shares during the quarter. Geode Capital Management LLC’s holdings in argenx were worth $16,732,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Franklin Resources Inc. lifted its stake in argenx by 0.4% in the fourth quarter. Franklin Resources Inc. now owns 134,591 shares of the company’s stock worth $82,774,000 after purchasing an additional 573 shares during the last quarter. O Shaughnessy Asset Management LLC increased its holdings in shares of argenx by 44.7% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 3,138 shares of the company’s stock worth $1,930,000 after buying an additional 969 shares during the period. Clearbridge Investments LLC lifted its stake in shares of argenx by 6.8% in the 4th quarter. Clearbridge Investments LLC now owns 629,828 shares of the company’s stock valued at $387,344,000 after acquiring an additional 40,330 shares during the last quarter. Intrust Bank NA purchased a new stake in argenx during the 4th quarter valued at about $383,000. Finally, BIT Capital GmbH grew its position in argenx by 22.1% during the 4th quarter. BIT Capital GmbH now owns 4,032 shares of the company’s stock worth $2,480,000 after acquiring an additional 731 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Price Performance

Shares of argenx stock opened at $596.20 on Monday. argenx SE has a 1 year low of $352.77 and a 1 year high of $678.21. The firm has a market cap of $36.23 billion, a price-to-earnings ratio of -677.50 and a beta of 0.60. The company has a 50-day moving average of $602.53 and a 200 day moving average of $606.37.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. On average, equities analysts anticipate that argenx SE will post 3.13 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on ARGX shares. Guggenheim boosted their price objective on argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a research report on Monday, March 10th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a “sell” rating to a “hold” rating in a report on Wednesday, March 12th. Citigroup raised their price target on shares of argenx from $681.00 to $796.00 and gave the stock a “buy” rating in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $720.00 price objective on shares of argenx in a research note on Tuesday, April 8th. Finally, Oppenheimer increased their target price on shares of argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $699.28.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.